TJX Stock: Wall Street Stays Bullish After Earnings
TJX stock is trading lower Wednesday despite the TJ Maxx owner's beat-and-raise quarter, but analysts aren't worried. Here's why.


TJX Companies (TJX) stock is lower Wednesday even after the off-price retailer and TJ Maxx parent beat top- and bottom-line expectations for its fiscal 2025 third quarter and raised its full-year outlook.
In the 13 weeks ended November 2, TJX's revenue increased 6% year over year to $14.1 billion, driven by comparable-store sales growth across all its brands and geographies, including 2% combined growth at TJ Maxx, Marshalls and Sierra and 3% collective growth at HomeGoods and HomeSense stores across its U.S. stores.
The retailer also said its earnings per share (EPS) rose 10.7% from the year-ago period to $1.14.

Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
"Our comparable-store sales increase of 3% was at the high-end of our plan, and both pretax profit margin and earnings per share came in well above our expectations," said TJX CEO Ernie Herrman in a statement. "Across the Company, customer transactions drove our comparable-store sales increases, which tells us that our values and treasure hunt shopping experience are appealing to a wide range of customers."
The results beat analysts' expectations. Wall Street was anticipating revenue of $13.95 billion and earnings of $1.10 per share, according to Yahoo Finance.
As a result of its "above-plan profitability results in the third quarter," TJX raised its full-year profit forecast. It now expects to achieve EPS in the range of $4.15 to $4.17, up from its previous forecast of $4.09 to $4.13. Management added that it continues to anticipate consolidated comparable-store sales to rise 3%.
For the fourth quarter, TJX said it expects to achieve comparable-store sales growth in the range of 2% to 3% and earnings per share between $1.12 to $1.14. However, the midpoint of this range, $1.13 per share, came up short of the average analyst estimate of approximately $1.18 per share.
"The fourth quarter is off to a strong start, and we are excited about our opportunities for the holiday selling season," Herrman said.
Is TJX stock a buy, sell or hold?
TJX has slightly outperformed the broader market in 2024, up 29% for the year to date on a total return basis (price change plus dividends) vs the S&P 500's 26% gain. And Wall Street is bullish on the consumer discretionary stock.
According to S&P Global Market Intelligence, the average analyst target price for TJX stock is $126.55, representing implied upside of roughly 7% to current levels. Meanwhile, the consensus recommendation is a Buy.
Financial services firm UBS Global Research is one of the more bullish outfits on TJX stock with a Buy rating and $148 price target.
"We think TJX's sales and EPS outlooks justify a premium valuation," said UBS analyst Jay Sole in a November 11 note. "We see TJX as a defensive stock well-positioned to continue to take market share from weaker channels, such as department stores. This should allow the company to deliver solid comparable-store sales growth and fixed cost leverage."
Related Content
- Kiplinger's Earnings Calendar for This Week
- Target Is the Worst S&P 500 Stock After Earnings. Here's Why
- Why Walmart Stock's a Buy After Its Beat-And-Raise Quarter
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

Joey Solitro is a freelance financial journalist at Kiplinger with more than a decade of experience. A longtime equity analyst, Joey has covered a range of industries for media outlets including The Motley Fool, Seeking Alpha, Market Realist, and TipRanks. Joey holds a bachelor's degree in business administration.
-
New Bill Would Lower Age to Contribute to 401(k)s to 18 from 21. What You Need to Know
The bipartisan Helping Young Americans Save for Retirement Act would lower the minimum age for participants in workplace retirement plans from 21 to 18.
-
Such Attractive Yields in High-Grade Munis Are Rare and May Not Last Long
According to this munis expert, the last time munis were this cheap was a brief period in 2023. If you kicked yourself for missing out then, you have a second chance now.
-
Such Attractive Yields in High-Grade Munis Are Rare and May Not Last Long
According to this munis expert, the last time munis were this cheap was a brief period in 2023. If you kicked yourself for missing out then, you have a second chance now.
-
Financial Analyst Sees a Bright Present for Municipal Bond Investors
High-tax-bracket investors have an excellent opportunity to secure low-volatility, high-quality returns at yield levels rarely seen in over a decade.
-
I'm an Insurance Pro: How Not to Get Dumped by Your Insurance Agent
Your insurance agent or broker might show you the door if you do any of these five things. Being a good customer is about more than paying your bill on time.
-
Stock Market Today: Stocks Climb More Walls of Worry
Volatility is back in a normal range, and the trend for the main equity indexes remains positive despite specific and general headwinds.
-
Is It Time to Invest in Europe?
Stock Market Europe is being shaken out of its lethargy, militarily and otherwise, by Donald Trump's changes in U.S. policy. Should investors start buying?
-
Two Estate Planning Issues You Should Never Overlook
This estate planning attorney explains why proper asset titling and beneficiary designations make a big difference when it's time to transfer your wealth.
-
The Four D's That Could Force You to Sell Your Business
Business owners (or their heirs) can be rushed into a sale of their company if they haven't planned for a major change in circumstances — or the four D's.
-
Stock Market Today: Nasdaq Outperforms as Big Tech Rallies
The Dow Jones Industrial Average closed lower for a second day as Amgen and Merck fell.